Court reverses Risperdal decision

Share this article:

The Arkansas Supreme Court has put $1.2 billion into Johnson & Johnson's accounts.

The court ruled last week that a previous ruling, which slapped the drugmaker for violating Medicaid fraud and deceptive marketing practices, was erroneous because the wrong standard was used.

As explained by Reuters, the court reversed the financial penalty because the court said plaintiffs invoked a law that applies to healthcare facilities, as opposed to a corporation.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.